Adicet Bio, Inc. (ACET) stock
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.78+0.03 (+1.09%)
Close on Nov 17, 2026Market cap $26.02MP/E –Yield –
Adicet Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Adicet Bio's operating income for the twelve months ending Jun 30, 2026 was -$103.71M. For fiscal 2025 it was -$122.11M. The highest annual figure on record is -$14.96M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$122.11M | – |
| FY2024 | Dec 31, 2024 | -$127.62M | – |
| FY2023 | Dec 31, 2023 | -$152.04M | – |
| FY2022 | Dec 31, 2022 | -$72.55M | – |
| FY2021 | Dec 31, 2021 | -$61.43M | – |
| FY2020 | Dec 31, 2020 | -$39.19M | – |
| FY2019 | Dec 31, 2019 | -$31.39M | – |
| FY2018 | Dec 31, 2018 | -$14.96M | – |
| FY2017 | Dec 31, 2017 | -$18.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.30M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.57M | – |
| Q4 FY2025 | Dec 31, 2025 | -$31.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$32.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$52.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$34.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.32M | -808.1% |
| Q4 FY2022 | Dec 31, 2022 | -$31.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.71M | – |
| Q1 FY2022 | Mar 31, 2022 | $4.71M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.35M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.63M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.56M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$15.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.69M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.03M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.20M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.95M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.06M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.36M | – |
See a number that looks wrong?